98%
921
2 minutes
20
Background: Serious but rare side effects associated with immunotherapy pose a difficult problem for regulators and practitioners. Immune checkpoint inhibitors (ICIs) have come into widespread use in oncology in recent years and are associated with rare cardiotoxicity, including potentially fatal myocarditis. To date, no comprehensive model of myocarditis progression and outcomes integrating time-series based laboratory and clinical signals has been constructed. In this paper, we describe a time-series neural net (NN) model of ICI-related myocarditis derived using supervised machine learning.
Methods: We extracted and modeled data from electronic medical records of ICI-treated patients who had an elevation in their troponin. All data collection was performed using an electronic case report form, with approximately 300 variables collected on as many occasions as available, yielding 6000 data elements per patient over their clinical course. Key variables were scored 0-5 and sequential assessments were used to construct the model. The NN model was developed in MatLab and applied to analyze the time course and outcomes of treatments.
Results: We identified 23 patients who had troponin elevations related to their ICI therapy, 15 of whom had ICI-related myocarditis, while the remaining 8 patients on ICIs had other causes for troponin elevation, such as myocardial infarction. Our model showed that troponin was the most predictive biomarker of myocarditis, in line with prior studies. Our model also identified early and aggressive use of steroid treatment as a major determinant of survival for cases of grade 3 or 4 ICI-related myocarditis.
Conclusion: Our study shows that a supervised learning NN can be used to model rare events such as ICI-related myocarditis and thus provide clinical insight into drivers of progression and treatment outcomes. These findings direct attention to early detection biomarkers and clinical symptoms as the best means of implementing early and potentially life-saving steroid treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376002 | PMC |
http://dx.doi.org/10.2147/CPAA.S369008 | DOI Listing |
Eur Heart J Case Rep
August 2025
Division of Cardiovascular Medicine, University of Virginia, PO Box 8000662, Charlottesville, VA 22908, USA.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are associated with various adverse effects, including myocarditis, with mortality rates up to 50%. We report a case of fatal ICI-related fulminant eosinophilic myo-pericarditis complicated by tamponade in a 69-year-old man with metastatic lung adenocarcinoma.
Case Summary: Two weeks after receiving one dose of pembrolizumab, the patient presented with sudden chest pain and dyspnoea.
Zhonghua Yi Xue Za Zhi
September 2025
Department of Neurology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003, China.
The clinical data and follow-up outcomes of 9 patients diagnosed with immune checkpoint inhibitor (ICI)-associated myasthenia gravis (MG) admitted to Henan Provincial People's Hospital from January 2021 to October 2024 were collected retrospectively to analyze their clinical characteristics and prognosis. Nine patients were enrolled, including 4 males and 5 females, aged [ (, )] 69 (55, 77) years. All patients had tumors and had received ICI treatment.
View Article and Find Full Text PDFFront Immunol
August 2025
Department of Cardiovascular Diseases, First Hospital of Jilin University, Jilin University, Changchun, China.
The emergence of immune checkpoint inhibitors (ICIs) have provided a new perspective for cancer immunotherapy. Immune checkpoint inhibitors significantly improve the survival prognosis of patients with various advanced cancers by inhibiting immune checkpoint molecules, thereby releasing the suppression of T cells by tumor microenvironment, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1). Immune checkpoint inhibitor (ICI) therapy, while effective, gives rise to distinct immune-related adverse events (irAEs), including cardiovascular toxicities, necessitating focused research efforts to better understand and address these specific complications.
View Article and Find Full Text PDFCancer Treat Rev
August 2025
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA. Electronic address:
Background: Immune checkpoint inhibitors (ICIs) have improved outcomes for various malignancies. However, serious immune-related adverse events (irAEs), including neurologic complications (NAEs), may occur. The aim of this study was to examine the incidence and spectrum of NAEs and evaluate management strategies for reducing their impact.
View Article and Find Full Text PDFStem Cell Res
September 2025
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:
Immune checkpoint inhibitors (ICI) are a pivotal class of immuno-oncology therapeutics that have improved survival rates for patients with cancer. Their widespread usage, however, is limited due to the development of serious and potentially deadly ICI-related side effects. To develop novel diagnostic and therapeutic strategies to identify and treat patients at risk, we need a better understanding of the underlying mechanisms mediating these potentially deadly side effects.
View Article and Find Full Text PDF